Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2000 Jul 24;83(4):447–453. doi: 10.1054/bjoc.2000.1307

Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer – a randomized trial with quality of life as the primary outcome

H Anderson 1, P Hopwood 2, R J Stephens 3, N Thatcher 4, B Cottier 5, M Nicholson 6, R Milroy 7, T S Maughan 8, S J Falk 9, M G Bond 10, P A Burt 11, C K Connolly 12, M B McIllmurray 13, J Carmichael 14
PMCID: PMC2374661  PMID: 10945489

Abstract

Three hundred patients with symptomatic, locally advanced or metastatic NSCLC not requiring immediate radiotherapy were enrolled into this randomized multicentre trial comparing gemcitabine + BSC vs BSC alone. Patients allocated gemcitabine received 1000 mg/m2on days 1, 8 and 15 of a 28-day cycle, for a maximum of six cycles. The main aim of this trial was to compare patient assessment of a predefined subset of commonly reported symptoms (SS14) from the EORTC QLQ-C30 and LC13 scales. The primary end-points were defined as (1) the percentage change in mean SS14 score between baseline and 2 months and (2) the proportion of patients with a marked (≥ 25%) improvement in SS14 score between baseline and 2 months sustained for ≥4 weeks. The secondary objectives were to compare treatments with respect to overall survival, and multidimensional QL parameters.The treatment groups were balanced with regard to age, gender, Karnofsky performance status (KPS) and disease stage (40% had metastatic disease). The percentage change in mean SS14 score from baseline to 2 months was a 10% decrease (i.e. improvement) for gemcitabine plus BSC and a 1% increase (i.e. deterioration) for BSC alone (P = 0.113, two-sample t -test). A sustained (≥ 4 weeks) improvement (≥25%) on SS14 was recorded in a significantly higher proportion of gemcitabine + BSC patients (22%) than in BSC alone patients (9%) (P = 0.0014, Pearson’s chi-squared test). The QLQ-C30 and L13 subscales showed greater improvement in the gemcitabine plus BSC arm (in 11 domains) than in the BSC arm (one symptom item). There was greater deterioration in the BSC alone arm (six domains/items) than in the gemcitabine + BSC arm (three QL domains). Tumour response occurred in 19% (95% CI 13–27) of gemcitabine patients. There was no difference in overall survival: median 5.7 months (95% CI 4.6–7.6) for gemcitabine + BSC patients and 5.9 months (95% CI 5.0–7.9) (log-rank, P = 0.84) for BSC patients, and 1-year survival was 25% for gemcitabine + BSC and 22% for BSC. Overall, 74 (49%) gemcitabine + BSC patients and 119 (79%) BSC patients received palliative radiotherapy. The median time to radiotherapy was 29 weeks for gemcitabine + BSC patients and 3.8 weeks for BSC. Patients treated with gemcitabine + BSC reported better QL and reduced disease-related symptoms compared with those receiving BSC alone. These improvements in patient-assessed QL were significant in magnitude and were sustained. © 2000 Cancer Research Campaign

Keywords: gemcitabine, BSC, NSCLC, quality of life

Full Text

The Full Text of this article is available as a PDF (79.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aapro M. S., Martin C., Hatty S. Gemcitabine--a safety review. Anticancer Drugs. 1998 Mar;9(3):191–201. doi: 10.1097/00001813-199803000-00001. [DOI] [PubMed] [Google Scholar]
  2. Aaronson N. K., Ahmedzai S., Bergman B., Bullinger M., Cull A., Duez N. J., Filiberti A., Flechtner H., Fleishman S. B., de Haes J. C. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993 Mar 3;85(5):365–376. doi: 10.1093/jnci/85.5.365. [DOI] [PubMed] [Google Scholar]
  3. Batel-Copel L. M., Kornblith A. B., Batel P. C., Holland J. C. Do oncologists have an increasing interest in the quality of life of their patients? A literature review of the last 15 years. Eur J Cancer. 1997 Jan;33(1):29–32. doi: 10.1016/s0959-8049(96)00414-5. [DOI] [PubMed] [Google Scholar]
  4. Bergman B., Aaronson N. K., Ahmedzai S., Kaasa S., Sullivan M. The EORTC QLQ-LC13: a modular supplement to the EORTC Core Quality of Life Questionnaire (QLQ-C30) for use in lung cancer clinical trials. EORTC Study Group on Quality of Life. Eur J Cancer. 1994;30A(5):635–642. doi: 10.1016/0959-8049(94)90535-5. [DOI] [PubMed] [Google Scholar]
  5. Brinkley D. Quality of life in cancer trials. Br Med J (Clin Res Ed) 1985 Sep 14;291(6497):685–686. doi: 10.1136/bmj.291.6497.685. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Cox J. D., Stetz J., Pajak T. F. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC) Int J Radiat Oncol Biol Phys. 1995 Mar 30;31(5):1341–1346. doi: 10.1016/0360-3016(95)00060-C. [DOI] [PubMed] [Google Scholar]
  7. Fernandez C., Rosell R., Abad-Esteve A., Monras P., Moreno I., Serichol M., Roviralta M. Quality of life during chemotherapy in non-small cell lung cancer patients. Acta Oncol. 1989;28(1):29–33. doi: 10.3109/02841868909111177. [DOI] [PubMed] [Google Scholar]
  8. Hardy J. R., Noble T., Smith I. E. Symptom relief with moderate dose chemotherapy (mitomycin-C, vinblastine and cisplatin) in advanced non-small cell lung cancer. Br J Cancer. 1989 Nov;60(5):764–766. doi: 10.1038/bjc.1989.355. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Hopwood P., Harvey A., Davies J., Stephens R. J., Girling D. J., Gibson D., Parmar M. K. Survey of the Administration of quality of life (QL) questionnaires in three multicentre randomised trials in cancer. The Medical Research Council Lung Cancer Working Party the CHART Steering Committee. Eur J Cancer. 1998 Jan;34(1):49–57. doi: 10.1016/s0959-8049(97)00347-x. [DOI] [PubMed] [Google Scholar]
  10. Hopwood P. Quality of life assessment in chemotherapy trials for non-small cell lung cancer: are theory and practice significantly different? Semin Oncol. 1996 Oct;23(5 Suppl 10):60–64. [PubMed] [Google Scholar]
  11. Hopwood P., Stephens R. J., Machin D. Approaches to the analysis of quality of life data: experiences gained from a medical research council lung cancer working party palliative chemotherapy trial. Qual Life Res. 1994 Oct;3(5):339–352. doi: 10.1007/BF00451726. [DOI] [PubMed] [Google Scholar]
  12. Hopwood P., Stephens R. J. Symptoms at presentation for treatment in patients with lung cancer: implications for the evaluation of palliative treatment. The Medical Research Council (MRC) Lung Cancer Working Party. Br J Cancer. 1995 Mar;71(3):633–636. doi: 10.1038/bjc.1995.124. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Noble S., Goa K. L. Gemcitabine. A review of its pharmacology and clinical potential in non-small cell lung cancer and pancreatic cancer. Drugs. 1997 Sep;54(3):447–472. doi: 10.2165/00003495-199754030-00009. [DOI] [PubMed] [Google Scholar]
  14. Pocock S. J., Simon R. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics. 1975 Mar;31(1):103–115. [PubMed] [Google Scholar]
  15. Randomised trial of four-drug vs less intensive two-drug chemotherapy in the palliative treatment of patients with small-cell lung cancer (SCLC) and poor prognosis. Medical Research Council Lung Cancer Working Party. Br J Cancer. 1996 Feb;73(3):406–413. doi: 10.1038/bjc.1996.71. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Stephens R. J., Hopwood P., Girling D. J. Defining and analysing symptom palliation in cancer clinical trials: a deceptively difficult exercise. Br J Cancer. 1999 Feb;79(3-4):538–544. doi: 10.1038/sj.bjc.6690085. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Stephens R. J., Hopwood P., Girling D. J., Machin D. Randomized trials with quality of life endpoints: are doctors' ratings of patients' physical symptoms interchangeable with patients' self-ratings? Qual Life Res. 1997 Apr;6(3):225–236. doi: 10.1023/a:1026458604826. [DOI] [PubMed] [Google Scholar]
  18. Thatcher N., Anderson H., Betticher D. C., Ranson M. Symptomatic benefit from gemcitabine and other chemotherapy in advanced non-small cell lung cancer: changes in performance status and tumour-related symptoms. Anticancer Drugs. 1995 Dec;6 (Suppl 6):39–48. doi: 10.1097/00001813-199512006-00007. [DOI] [PubMed] [Google Scholar]
  19. Thatcher N., Hopwood P., Anderson H. Improving quality of life in patients with non-small cell lung cancer: research experience with gemcitabine. Eur J Cancer. 1997 Jan;33 (Suppl 1):S8–13. doi: 10.1016/s0959-8049(96)00336-x. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES